These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 8934608)
21. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G; Cerasi E Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909 [TBL] [Abstract][Full Text] [Related]
22. Genetic cause of hyperglycaemia and response to treatment in diabetes. Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972 [TBL] [Abstract][Full Text] [Related]
23. [Clinically important effects of oral antidiabetic drug interactions]. Drzewoski J; Kopff B Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985 [TBL] [Abstract][Full Text] [Related]
24. Role of metformin in treatment of diabetes mellitus. Vigneri R; Goldfine ID Diabetes Care; 1987; 10(1):118-22. PubMed ID: 3552509 [TBL] [Abstract][Full Text] [Related]
25. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Fisman EZ; Tenenbaum A; Motro M; Adler Y Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955 [TBL] [Abstract][Full Text] [Related]
26. [Therapeutic utility of biguanides in the treatment of NIDDM]. Fujimoto S Nihon Rinsho; 1999 Mar; 57(3):657-62. PubMed ID: 10199150 [TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of type 2 diabetes mellitus. Rendell MS; Kirchain WR Ann Pharmacother; 2000; 34(7-8):878-95. PubMed ID: 10928401 [TBL] [Abstract][Full Text] [Related]
29. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons". Heine RJ Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Marchetti P; Giannarelli R; di Carlo A; Navalesi R Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological treatment of type 2 diabetes. Hermans MP; Buysschaert M Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468 [No Abstract] [Full Text] [Related]
32. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Jennings PE Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327 [TBL] [Abstract][Full Text] [Related]
34. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Standl E; Schnell O Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474 [No Abstract] [Full Text] [Related]
35. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus. Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007 [TBL] [Abstract][Full Text] [Related]
39. [Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?]. Mehnert H Dtsch Med Wochenschr; 1989 Jul; 114(27):1086-8. PubMed ID: 2500320 [No Abstract] [Full Text] [Related]
40. Rational use of oral hypoglycaemic drugs. Taft P Drugs; 1979 Feb; 17(2):134-9. PubMed ID: 456290 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]